Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

SAN DIEGO, May 2, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the first quarter ended March 31, 2013.

During the first quarter of 2013, Cadence reported net product revenue from sales of OFIRMEV® (acetaminophen) injection of $23.6 million, which includes the one-time recognition of $2.6 million in deferred revenue on previously shipped product. Consistent with other companies with products at this stage of commercialization, and based upon its determination it had obtained sufficient product return history to reasonably estimate future wholesaler returns, beginning on January 1, 2013, the company began to recognize revenue at the time that the product is sold to a wholesaler.

Excluding the recognition of $2.6 million in previously deferred revenue, net product revenue for the first quarter of 2013 was $21.0 million, which represents an increase of more than 160% from the $8.0 million in net product revenue recognized for the first quarter of 2012, and an increase of 23% from the $17.1 million recognized for the fourth quarter of 2012.

Highlights for the first quarter of 2013 included:

  • The gross margin on sales of OFIRMEV was 65% for the first quarter of 2013, as compared to 47% for the first quarter of 2012.
  • As of March 31, 2013, the company had over 4,000 unique customer accounts, an increase of nearly 50% from the first quarter of 2012.
  • The average order size by end-user customers increased 28% during the first quarter of 2013 as compared to the first quarter of 2012.
  • On March 12, 2013, the company announced that the Department of Veterans Affairs added OFIRMEV to the VA Natio
    '/>"/>

  • SOURCE Cadence Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
    2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
    3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
    4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
    5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
    6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
    7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
    8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
    9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
    10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
    11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/3/2015)... 3, 2015 /CNW/- SQI Diagnostics Inc. (TSX:V: SQD), a life ... and products for advanced microarray diagnostics, today announced ...  to its Management team. In his capacity as ... transition from a development stage to a commercially ... the Company,s capital market strategy and to secure ...
    (Date:3/3/2015)... (PRWEB) March 03, 2015 Crown Bioscience, ... company, has launched a new Life Science division specializing ... preclinical research. , The first products released include ... controls, and soon to be released in vivo grade ... continue to expand their life science portfolio with additional ...
    (Date:3/3/2015)... Milpitas, Calif. (PRWEB) March 03, 2015 ... risk management excellence were honored by the Global ... annual event which took place on Wednesday, February 25th, ... , The GSCRC was formed to bring together supply ... thought leaders to advance the professional discipline through opportunities ...
    (Date:3/3/2015)... 2015  Thingee Corporation, a software development company for ... entitled, "Technology Adoption: Making Reps, Lives Easier" during the ... Technology ,  in Deerfield Beach, Florida ... Audiences looking to learn how technology can help them ... in the audience for the Thingee presentation. ...
    Breaking Biology Technology:SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Crown Bioscience Launches Life Science Product Catalog 2Global Supply Chain Resiliency Council Names Award Winners 2Global Supply Chain Resiliency Council Names Award Winners 3Global Supply Chain Resiliency Council Names Award Winners 4Thingee to present at 11th Annual Synergistix Users Conference 2
    ... 12 Abbott today is,announcing its full-year earnings-per-share ... earnings-per-share guidance of $3.31 to $3.33,excluding specified items. ... share,of $3.65 to $3.70 under Generally Accepted Accounting ... midpoint of this 2009 guidance reflects double-digit,growth over ...
    ... -- American Oriental,Bioengineering, Inc. (NYSE: AOB ... and manufacturer of pharmaceutical and healthcare products in,China, ... undertake one-on-one,meetings at the 2009 UBS Greater China ... Management is currently scheduled to meet with,institutional ...
    ... MAP,Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced ... Dose Budesonide (UDB) for children,with asthma and MAP0004 for ... have completed the 12 week treatment period in the ... currently expects to complete,enrollment in its initial Phase 3 ...
    Cached Biology Technology:Abbott Announces Earnings Guidance for 2009 2MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs 2MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs 3
    (Date:1/22/2015)... 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), the ... campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz will ... capacity to meet customer demand. Logo ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by Dr. ...
    (Date:1/22/2015)...  BellBrook Labs, a leader in high throughput screening ... a TR-FRET (time resolved Forster resonance energy transfer) ... high throughput screening assay for glycosyltransferases and other ... sensitive detection of hundreds of human and microbial ...
    (Date:1/22/2015)... Inc. (NASDAQ: NXTD and NXTDW) a biometric authentication company ... of the Wocket™ smart wallet at CES 2015 in Las ... one of the "11 Hot Products at CES" in a review published ... Far" by Newseveryday.com and "The top 10 gadgets from CES 2015" by ...
    Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
    ... of Fame awards will be presented on April 3 at ... Hall of Fame, established in 1981, serves as a posthumous ... other individual who has been an active member of the ... This year,s awards will honor Fred Winsberg, MD, Martin Resnick, ...
    ... report that IDO, an enzyme found throughout the body and ... fact essential to the onset of depressive symptoms sparked by ... the Journal of Immunology , is the first to ... induces depressive symptoms in some cases of chronic inflammation. ...
    ... CHAMPAIGN, Ill. As school districts across the nation ... "No Child Left Behind" Act, opportunities for children to ... Future mandates, however, might be better served by ... study suggesting the academic benefits of physical education classes, ...
    Cached Biology News:AIUM presents 2009 Memorial Hall of Fame awards 2Team identifies a molecular switch linking infectious disease and depression 2Team identifies a molecular switch linking infectious disease and depression 3Physical activity may strengthen children's ability to pay attention 2Physical activity may strengthen children's ability to pay attention 3Physical activity may strengthen children's ability to pay attention 4
    ...
    ... new application for DNA and protein ... Expression makes complex computational analyses of ... the very latest computing technology to ... sequences are analysed. Features include: Sequence ...
    ... Solution is a comprehensive suite of ... specifically designed to reliably extract biological ... genomic studies containing thousands of samples, ... efficient and will analyze large data ...
    ...
    Biology Products: